SPIKEVAX
The FDA has updated the approved indications for SPIKEVAX to include active immunization against COVID-19 specifically for individuals 65 years and older, and those aged 6 months through 64 years with at least one underlying condition.
This update affects the manufacturer of SPIKEVAX, healthcare providers administering the vaccine, and regulatory affairs professionals responsible for labeling compliance and clinical documentation.
The specification of 'at least one underlying condition' for the 6-month to 64-year age bracket narrows the indicated population for this specific biologics license. This suggests a shift toward a risk-based indication for younger populations. Regulatory departments must ensure that all physician labeling and patient information materials precisely reflect these demographic and health-status restrictions to maintain compliance.
Regulatory and labeling teams should verify that current product inserts and promotional materials align with these specific age and health status parameters. Clinical affairs departments may need to update internal documentation regarding the approved indications for use to ensure accurate reporting and surveillance.
For active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).<br> <br> SPIKEVAX is approved for use in individuals who are:<br> <br> 65 years of age and older, or<br> <br> 6 months through 64 years of age with at least one underlying condition
Open in openFDA / FDA.gov